aTyr Pharma, Inc. (ATYR)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$0.17-2.88%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge aTyr Pharma, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	9.74M
EPS	—	-0.094
Annual ending 2026-12-31
Revenue	—	3.86M
EPS	—	-0.411
Annual ending 2027-12-31
Revenue	—	8.79M
EPS	—	-0.374

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Advance efzofitimod development in pulmonary sarcoidosis	A primary condition in aTyr Pharma, Inc.'s published investment case. The stated target is positive regulatory and clinical updates by end 2026.	Improving	lack of positive regulatory or clinical progress through 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management has consistently emphasized focusing resources on efzofitimod development including a planned Phase 3 study in pulmonary sarcoidosis and completion of the Phase 2 EFZO-CONNECT study. Cash and investments declined from $68.3M in 2026-Q1 to $58.9M in 2026-Q2, with R&D expenses slightly decreasing from $7.3M to $6.7M. The trajectory shows continued investment and focus on efzofitimod development, delivering on stated priorities. Delivery assessment Oct 24, 2026
Address Nasdaq listing compliance issues	A supporting condition in aTyr Pharma, Inc.'s published investment case. The stated target is maintain bid price above $1.00 and satisfy Nasdaq requirements through 2026.	Under Pressure	failure to regain Nasdaq compliance or delisting occurs	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q2. The company received a Nasdaq deficiency notice due to the bid price closing below $1.00 per share for 30 consecutive business days. No further updates on resolution or progress were provided in subsequent quarters, indicating limited progress on this regulatory priority. Delivery assessment Oct 24, 2026
Manage operating losses and cash burn	The company manages cash burn while pursuing regulatory progress.	Intact	operating loss worsens beyond -$11.4M per quarter	Operating income: $-10.881M FY2026-Q2; GAAP. Published target: operating loss improves to better than -$11.4M per quarter. Target period is not explicitly aligned with this observation. Source published Aug 7, 2026-10,881,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0f887002-7102-464d-bdf9-231ea064672a. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management has implemented a workforce reduction of about 60% and expects to reduce annualized operating expenses by approximately $13M starting Q4 2026. Operating expenses decreased from $20.3M in 2025-Q4 to $10.9M in 2026-Q2, and net loss improved from -$13.9M to -$10.3M over the same period. The trajectory shows progress in managing losses and cash burn consistent with management's stated cost discipline. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.37

$-0.61 → $-0.37 · observed estimates

FY2027 revenue$0.01B

$0.00B → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.61	$0	9 / 9
2026-07-25	$-0.61	$0	9 / 9
2026-07-26	$-0.61	$0	9 / 9
2026-07-27	$-0.61	$0	9 / 9
2026-07-28	$-0.61	$0	9 / 9
2026-07-29	$-0.61	$0	9 / 9
2026-07-30	$-0.61	$0	9 / 9
2026-07-31	$-0.61	$0	9 / 9
2026-08-01	$-0.61	$0	9 / 9
2026-08-02	$-0.61	$0	9 / 9
2026-08-03	$-0.61	$0	9 / 9
2026-08-04	$-0.61	$0	9 / 9
2026-08-05	$-0.61	$0	9 / 9
2026-08-06	$-0.61	$0	9 / 9
2026-08-07	$-0.64	$8,787,375	6 / 6
2026-08-08	$-0.61	$0	9 / 9
2026-08-09	$-0.61	$0	9 / 9
2026-08-10	$-0.61	$0	9 / 9
2026-08-11	$-0.61	$0	9 / 9
2026-08-12	$-0.51	$0	9 / 9
2026-08-13	$-0.51	$0	9 / 9
2026-08-14	$-0.64	$8,787,375	6 / 6
2026-08-15	$-0.64	$8,787,375	6 / 6
2026-08-16	$-0.64	$8,787,375	6 / 6
2026-08-17	$-0.64	$8,787,375	6 / 6
2026-08-18	$-0.64	$8,787,375	6 / 6
2026-08-19	$-0.64	$8,787,375	6 / 6
2026-08-20	$-0.64	$8,787,375	6 / 6
2026-08-21	$-0.44	$8,787,375	6 / 6
2026-08-22	$-0.44	$8,787,375	6 / 6
2026-08-23	$-0.44	$8,787,375	6 / 6
2026-08-24	$-0.44	$8,787,375	6 / 6
2026-08-25	$-0.44	$8,787,375	6 / 6
2026-08-26	$-0.44	$8,787,375	6 / 6
2026-08-27	$-0.44	$8,787,375	6 / 6
2026-08-28	$-0.44	$8,787,375	6 / 6
2026-08-29	$-0.44	$8,787,375	6 / 6
2026-08-30	$-0.44	$8,787,375	6 / 6
2026-08-31	$-0.44	$8,787,375	6 / 6
2026-09-01	$-0.44	$8,787,375	6 / 6
2026-09-02	$-0.44	$8,787,375	6 / 6
2026-09-03	$-0.44	$8,787,375	6 / 6
2026-09-04	$-0.44	$8,787,375	6 / 6
2026-09-05	$-0.44	$8,787,375	6 / 6
2026-09-06	$-0.44	$8,787,375	6 / 6
2026-09-07	$-0.44	$8,787,375	6 / 6
2026-09-08	$-0.44	$8,787,375	6 / 6
2026-09-09	$-0.44	$8,787,375	6 / 6
2026-09-10	$-0.44	$8,787,375	6 / 6
2026-09-11	$-0.44	$8,787,375	6 / 6
2026-09-12	$-0.44	$8,787,375	6 / 6
2026-09-13	$-0.44	$8,787,375	6 / 6
2026-09-14	$-0.44	$8,787,375	6 / 6
2026-09-15	$-0.44	$8,787,375	6 / 6
2026-09-16	$-0.44	$8,787,375	6 / 6
2026-09-17	$-0.44	$8,787,375	6 / 6
2026-09-18	$-0.44	$8,787,375	6 / 6
2026-09-19	$-0.44	$8,787,375	6 / 6
2026-09-20	$-0.44	$8,787,375	6 / 6
2026-09-21	$-0.44	$8,787,375	6 / 6
2026-09-22	$-0.44	$8,787,375	6 / 6
2026-09-23	$-0.44	$8,787,375	6 / 6
2026-09-24	$-0.44	$8,787,375	6 / 6
2026-09-25	$-0.44	$8,787,375	6 / 6
2026-09-26	$-0.44	$8,787,375	6 / 6
2026-09-27	$-0.44	$8,787,375	6 / 6
2026-09-28	$-0.44	$8,787,375	6 / 6
2026-09-29	$-0.44	$8,787,375	6 / 6
2026-09-30	$-0.44	$8,787,375	6 / 6
2026-10-01	$-0.44	$8,787,375	6 / 6
2026-10-02	$-0.44	$8,787,375	6 / 6
2026-10-03	$-0.44	$8,787,375	6 / 6
2026-10-04	$-0.44	$8,787,375	6 / 6
2026-10-05	$-0.44	$8,787,375	6 / 6
2026-10-06	$-0.44	$8,787,375	6 / 6
2026-10-07	$-0.44	$8,787,375	6 / 6
2026-10-08	$-0.44	$8,787,375	6 / 6
2026-10-09	$-0.44	$8,787,375	6 / 6
2026-10-10	$-0.44	$8,787,375	6 / 6
2026-10-11	$-0.44	$8,787,375	6 / 6
2026-10-12	$-0.44	$8,787,375	6 / 6
2026-10-13	$-0.44	$8,787,375	6 / 6
2026-10-14	$-0.44	$8,787,375	6 / 6
2026-10-15	$-0.44	$8,787,375	6 / 6
2026-10-16	$-0.44	$8,787,375	6 / 6
2026-10-17	$-0.44	$8,787,375	6 / 6
2026-10-18	$-0.44	$8,787,375	6 / 6
2026-10-19	$-0.44	$8,787,375	6 / 6
2026-10-20	$-0.44	$8,787,375	6 / 6
2026-10-21	$-0.44	$8,787,375	6 / 6
2026-10-22	$-0.44	$8,787,375	6 / 6
2026-10-23	$-0.37	$8,787,375	6 / 6
2026-10-24	$-0.37	$8,787,375	6 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	4	6
2026-06-01	4	5
2026-07-01	4	5
2026-08-01	4	5
2026-09-01	4	5
2026-10-01	4	5

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 4 Buy / Strong Buy · 5 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Advance efzofitimod development in pulmonary sarcoidosisDirect metric needs a verified mapping
Address Nasdaq listing compliance issuesPublished status: Under Pressure
Manage operating losses and cash burnOperating income: $-10.881M

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.3%Typical daily move · historical

Downside history

-84.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

aTyr Pharma, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk, loss-making clinical-stage biotechnology company, so its multi-year view depends more on development progress than on established earnings. The thesis is intact, with management focused on efzofitimod and cost control, but evidence remains limited and model confidence is low.

What's priced into aTyr Pharma, Inc.

The valuation carries a premium versus peers, supported by the possibility that efzofitimod development creates future opportunity. That optionality is difficult to assess, and the evidence does not show exactly what level of clinical success the market assumes. No valuation fragility gates were triggered.

What the fundamentals likely do

Near-term results are likely to remain loss-making while ATYR advances its studies, though operating expenses and net losses have declined and management expects further annualized cost savings starting in Q4 2026. Enrollment in the Phase 2 EFZO-CONNECT study was completed, with topline results expected in Q1 2027. Cash and investments declined in the latest quarter, while litigation and a near-term earnings miss risk add uncertainty.

What aTyr Pharma, Inc. hinges on

Over the next year, the key test is whether EFZO-CONNECT results support further development, including the planned Phase 3 study in pulmonary sarcoidosis. The thesis also depends on sustaining cost discipline without undermining development, and on managing the cash balance as spending continues. Broader healthcare-sector strength may help sentiment, but weaker economic data or a guidance cut would be unfavorable risks.